Document is current
Any future updates will be listed below
-
Authors
Yao, Hao
Ren, Shi-hui
Wang, Lin-hui
Ren, Ming-qiang
Cai, Jiao
Chen, Dan
He, Ying
Lai, Si-han
Dou, Bai-tao
Li, Meng-jiao
Li, Yan-ling
Cen, Ya-li
Chang, Alex H.
Su, Yi
Qiu, Ling
Fan, Fang-yi
-
Funding
Funding for this research was provided by:
Sichuan Provincial Science and Technology Support Program (2024NSFSC1292, 2021YJ0145)
the general program of General Hospital of Western Theater Command (2021-XZYG-B32)
the incubation program of General Hospital of Western Theater command (2021-XZYG-C45, 2021-XZYG-C46)
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 14 May 2025
First Online: 19 May 2025
Declarations
:
: This study was approved by the Ethics Committee of People's Liberation Army The General Hospital of Western Theater Command (Approval Number: 2024EC1-ky033). All experiments were conducted in compliance with relevant ethical guidelines and regulations.
: Not applicable.
: Declaration of interests AHC is a founding member of Shanghai YaKe Biotechnology, a biotechnology company focusing on research and development of tumour cellular immunotherapy. All other authors declare no competing interests.
